NDAINJECTIONINJECTABLEPriority Review
Approved
Oct 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SANDOSTATIN (octreotide acetate) is a somatostatin analog administered by injection used to treat acromegaly, neuroendocrine tumors, and variceal bleeding. It works by binding somatostatin receptors to inhibit hormone secretion and reduce symptoms in patients with hormone-secreting tumors.
$0.169BPart D
LOE ApproachingAs LOE approaches, brand teams are shifting focus from growth to retention and managed decline; smaller commercial footprint expected within 2-3 years.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy Subjects
Started Jul 2014
24 enrolled
Drug Interactions
Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas
Started Nov 2011
256 enrolled
Neuroendocrine TumorsAdvanced Cancer
Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers
Started May 2010
43 enrolled
Neuroendocrine Carcinoma
Sandostatine® LP and Hyperinsulinism
Started May 2009
10 enrolled
Congenital Hyperinsulinism
Sandostatin for Patients With Androgen Independent Prostate Cancer
Started Jul 2007
13 enrolled
Prostate Cancer
Worked on SANDOSTATIN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.